



00-000000000



258202

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: _____ **Date:** 7/2/2026
Patient ID: _____ **Patient Date Of Birth:** _____
Patient Group No: _____ **Patient Phone:** _____ **Physician Name:** _____
NPI#: _____ **Specialty:** _____
Physician Office Telephone: _____
Physician Office Address: _____
Drug Name (specify drug): _____
Quantity: _____ **Frequency:** _____ **Strength:** _____
Route of Administration: _____ **Expected Length of Therapy:** _____
Diagnosis: _____ **ICD Code:** _____
Comments: _____

Please check the appropriate answer for each applicable question.

1. What is the patient's diagnosis?

Carcinosarcoma (malignant mixed Mullerian tumors) (If checked, go to 2)	☐	
Clear cell carcinoma of the ovary (If checked, go to 2)	☐	
Epithelial ovarian cancer (If checked, go to 2)	☐	
Fallopian tube cancer (If checked, go to 2)	☐	
Grade 1 endometrioid carcinoma (If checked, go to 2)	☐	
Low-grade serous carcinoma (If checked, go to 2)	☐	
Primary peritoneal cancer (If checked, go to 2)	☐	
Other, please specify. (If checked, no further questions)	☐	
2. Is this a request for continuation of therapy with the requested medication?

	Y ☐	N ☐
--	----------------------------	----------------------------
3. Is there evidence of unacceptable toxicity while on the current regimen?

	Y ☐	N ☐
--	----------------------------	----------------------------
4. Is there evidence of disease progression while on the current regimen?

	Y ☐	N ☐
--	----------------------------	----------------------------
5. What is the clinical setting in which the requested drug will be used?

Platinum-resistant persistent disease (If checked, go to 6)	☐	
Platinum-resistant recurrent disease (If checked, go to 6)	☐	
Other, please specify. (If checked, no further questions)	☐	
6. Has the patient received at least one prior systemic treatment regimen which included bevacizumab?

	Y ☐	N ☐
--	----------------------------	----------------------------
7. Will the requested drug be used in combination with nab-paclitaxel (Abraxane)?

	Y ☐	N ☐
--	----------------------------	----------------------------

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.